Introduction:
Candidemia is a well recognized clinical challenge in critical care today, the reasons being multiple. Candida is the fourth most common etiological agent of nosocomial bloodstream infections (BSIs) and accounts for about 12% of hospital acquired BSIs. The expanding population of immunocompromised patients due to rapid advancements in medicine has led to a new group of susceptible hosts to this fungus and a new problem of anti-fungal resistance is now in the limelight, more so with the non-Candida albicans (NAC) which is well documented in many recent studies across the world. A systematic review based on geographic region and study design done by Falagas et al stressed on the need for local epidemiological data to know the significance of candidemia, the species variability and expression of anti-fungal resistance. 1 The Prospective Anti-fungal therapy alliance (PATH) study by Pfaller et al between 2004 Pfaller et al between -2008 reported an increased incidence of 54.4% of non-C. albicans. 2 This emergence of NAC and less common species is also attributed to greater emphasis on species identification as a guide to initiate treatment choices. Thus, variability in species distribution across centres and expression of anti-fungal resistance necessitates strong local epidemiological study. 3 But few reports on unique country specific epidemiology are available for candidemia in Indian critical care settings. [4] [5] [6] [7] A recent study by Chakrabarti et al determined epidemiological and clinical parameters of candidemia cases among ICU patients across 25 hospitals in India. 8 The need for such comparative data for the real significance of candidemia as a nosocomial infection in our hospital and the lack of local epidemiological data to aid the diagnosis and treatment of this group of patients prompted us to conduct this study. The aim of our study was to speciate Candida isolates from blood cultures, to determine the risk factors associated with candidemia and to evaluate the anti-fungal susceptibility pattern in these isolates.
Materials & Methods:
This was a retrospective cohort study at a tertiary multi-specialty centre between the period of May 2013 to December 2014 conducted for a period of 20 months. Blood samples were collected aseptically in Bact Alert 3D culture bottles and incubated at 37 ○ C for 7 days in BacT/ALERTX® 3D automated microbial detection system. Subsequent samples were also collected during the course of treatment from some patients. When BacT Alert indicated positive, the bottles were unloaded, preliminary Gram stain was made to look for yeast-like cells and subcultures were made on 5% sheep blood agar and Sabouraud's dextrose agar and incubated at 25°C and 37°C. The colonies appeared within 24 hours of incubation in all the cases. Speciation of these isolates was further done using (a) germ tube production, (b) pigmentation on chromogenic medium (HiCHROM Candida agar) (c) chlamydospore formation and (d) carbohydrate assimilation tests using the VITEK 2 compact system (BioMérieux). Quality control measures were undertaken with reference strains C. krusei ATCC 6258 and ATCC 22019. Anti-fungal susceptibility was also done against fluconazole, flucytosine, voriconazole and amphotericin-B, caspofungin and micafungin in VITEK 2 compact system. Following interpretive susceptible criteria for anti-fungals were used. For fluconazole, breakpoints were as follows: susceptible(S), MIC ≤8 µg/ml; susceptible-dose dependent (SDD), MIC = 16 to 32 µg/ml; resistant(R), MIC ≥64 µg/ml. For flucytosine, isolates showing MIC's ≤4 µg/ml were considered as susceptible, 8-16 µg/ml as intermediate and ≥32 µg/ml as resistant. For voriconazole, breakpoints followed were: susceptible ≤1.0 µg/ml, 2.0 µg/ml as dosedependent and ≥4 µg/ml as resistant. For amphotericin-B, isolates showing a MIC of ≤1.0 µg/ml were taken as susceptible and those with MIC >1 µg/ml were considered as resistant ( Table I) .
Categorical data of demographic and clinical parameters were analyzed using Chi-square and Fisher's exact tests, as appropriate. A p-value < 0.05 was considered statistically significant. Candidemic patients treated with antifungals were followed up for outcome and the effect of nosocomial candidemia on mortality was assessed.
Results:
There were 56 episodes of candidemia in 46 patients during the study period. Of the 12,637 blood culture samples processed, 1088 had indicated positive (8.60 %). Among the total blood culture positives, 5.15% (1088/12,637) were cases of candidemia. All 46 patients were admitted in the intensive care units (100%). Seven patients had more than one episode of candidemia. Out of the 56 blood isolates of various Candida species, the most common was C. tropicalis (33.92%). It was followed by C. albicans, C. glabrata, C. haemulonii, C. parapsilosis, C. famata, C. guilliermondii and C. lusitaniae ( Figure I) . Majority of the infected patients were males (72%). Patients having candidemia belonged to the age group ranging from 17 days to 89 years with a mean of 54.82 years( Figure II) . The length of hospitalization ranged from 1 to 67 days with an average duration of stay in the hospital of ~19.86 days. A number of predisposing factors were found among the candidemia cases. The majority of patients had multiple predisposing factors that have been associated with candidemia. For 33 patients (71.73%), ≥3 risk factors were identified ( Figure III) . The risk factors which were found to be associated with candidemia with p-value <0.05 considered significant were-antibiotic therapy (95.65%), invasive mechanical ventilation (60.86%), diabetes mellitus(58.69%), recent surgery (58.69%), use of central venous catheters (28.26%), chemotherapy (19.56%), dialysis (15.21%) and total parenteral nutrition (10.86%)( Table II) . Dose-dependent susceptibility to fluconazole was seen in 16.27 % (7/43) of NAC isolates. Fifty percent (3/6) of C. haemulonii isolates were resistant to Amphotericin-B. All isolates showed ~ 100 % susceptibility to echinocandins (Table III) . Anti-fungal therapy was instituted in 24 patients after blood culture results. Fluconazole was the commonly administered anti-fungal for 54.16% (13/24) of the treated patients. Fluconazole was escalated to caspofungin in five patients based on the anti-fungal susceptibility results (Table IV) . The clinical outcome of patients with candidemia, both C. albicans & NAC are summarized ( Table V) . The mortality rate in our study was 47.8% (22/46). Mortality was higher in patients with non-albicans candidemia (59%) when compared to those with candidemia due to C. albicans (41%). We also looked at the mean serum procalcitonin levels in these patients during candidemia episodes which was 3.99 ng/ mL (Figure IV) . (2) studies from India. 4-7 C. glabrata, C. haemulonii, C. parapsilosis, C. famata, C. guilliermondii & C. lusitaniae were the other NAC isolates. Prophylactic antifungal therapy is not a routine practice in our institute. Restricted use of anti-fungals is practiced and anti-fungal therapy is initiated on evidence of positive fungal culture reports unless the patients fall in the high risk category of candidemia and are suffering from high-grade fever with negative bacterial blood cultures, antifungal therapy is initiated empirically in such cases. Fluconazole was the commonest targeted therapy, followed by caspofungin in this group of patients of our study. C. haemulonii (6) was a highly resistant species showing less activity against amphotericin-B and azoles which can be attributed to intrinsic resistance. The mortality rate of 47.8 % in our study on comparison to another recent study by Adhikar et al in our region in which it was 37 % has thus shown an increase in fatal cases of candidemia over the recent years, although this falls within the range of 10-49%. 5 Mortality in candidemic patients occurs due to multiple factors like age of the patient, underlying co-morbid conditions, timing of the treatment, concomitant infections and prompt administration of appropriate antibiotic or anti-fungal therapy. Therefore, only an attributable mortality can be determined if we compare these statistics with other suitable controls in a case-control study. As this was not a case-control study, only crude mortality could be determined. The role of serum procalcitonin in fungal sepsis is an interesting area of research, which may help to differentiate candidemia from bacterial sepsis. The limitations of our study were that this was a single institution study with retrospective design. There is lack of uniformity in clinical practice with regards to empiric therapy based on local epidemiology; also there were small number of isolates of C. haemulonii, C. parapsilosis, C. famata, C. guilliermondii and C. lusitaniae with limited follow-up. Assessing risk factors and more active screening can shorten the diagnostic delays in candidemia especially in the intensive care settings. A bedside scoring system-'CANDIDA SCORE' as described by Leon et al in patients admitted to the ICUs should be used by clinicians. Four independent risk factors: multi-focal Candida species colonization, surgery upon ICU admission, severe sepsis, and total parenteral nutrition (TPN) are considered in this scoring tool. The Candida score is obtained by adding the statistical weight of each risk factor: clinical sepsis (2 points), surgery (1 point), TPN (1 point), and multifocal colonization (1 point).
9 A Candida Score of >2.5 is associated with a >7-fold increase in the likelihood of documented Candida infection. 9 Integrated effort on the part of all treating physicians and microbiologists to restrict risk factors especially the use of antibiotics, central venous lines, total parenteral nutrition, mechanical ventilation and long stay in the hospital especially in intensive care should be the primary goal in a preventive direction. Life threatening candidemia in patients admitted in tertiary set-ups for treatment of a primary disease can be prevented with close monitoring of species distribution of Candida and antifungal resistance like it is being done in few centres in India.
10 National guidelines for a rational empiric anti-fungal usage should be established for better treatment and outcome of patients with candidemia; more hospital-based epidemiological studies for comparison is also the need of the hour.
